Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03570918
Other study ID # CP-MGD014-01
Secondary ID 272201500032C-2-
Status Completed
Phase Phase 1
First received
Last updated
Start date September 25, 2018
Est. completion date September 28, 2021

Study information

Verified date August 2022
Source MacroGenics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).


Description:

Eligible participants will be maintained on ART and receive either one infusion (Part 1) or multiple infusions of MGD014 (Part 2). Part 1 is a single ascending dose study with a 1+3 design for the first 2 dose cohorts, and a 3+3 design with staggered accrual for the 6 higher dose cohorts, with an aim of determining the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ascending doses up to either the Optimal Biologic Dose (OBD) or the maximum administered dose (MAD). Part 2 is a multi-dose expansion cohort with MGD014 administered at the OBD, as determined in Part 1. In Part 2, additional assessments on the effects of MGD014 on HIV latent infection parameters will be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date September 28, 2021
Est. primary completion date September 28, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Ability and willingness of participant to provide written informed consent. - HIV-1 infection, documented by any FDA-approved rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load. - On a potent, stable, continuous ART regimen for = 24 months prior to Screening. - Plasma HIV-1 RNA < 50 copies/mL at two time points in the previous 12 months prior to screening (one time point can be screening) and never = 50 copies/mL on 2 consecutive time points in the last 24 months. - Adequate organ function based on acceptable laboratory parameters. Exclusion Criteria: - Women of childbearing potential defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or menopause. - History or other evidence of severe illness, immunodeficiency other than HIV, or any other condition that would make the potential participant unsuitable for study. - History or other evidence of any condition or process for which signs or symptoms could be confused with reactions to MGD014. - History of any HIV immunotherapy or HIV vaccine except for MGD014 within 12 months prior to screening. - History of clinically significant cardiovascular disease, severe allergic reactions, malignancy (except non-melanoma skin cancer) within 5 years, seizure disorder within 2 years, organ/tissue transplant, autoimmune disease, unstable asthma, bleeding disorder. - Evidence of active viral, or antifungal treatment within 7 days prior to the initiation of study drug - Active, asymptomatic, or suspected COVID-19/SARS-CoV-2 infection. - Active, untreated syphilis. - Use of blood products, cytokine therapy, growth-stimulating factors, cytotoxic chemotherapy or investigational therapy within 90 days. - Current use of the antivirals maraviroc and/or enfuvirtide. - Any vaccination with exception of flu vaccine within 30 days of screening.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
MGD014
HIV-1 x CD3 bispecific DART molecule

Locations

Country Name City State
United States University of North Carolina Chapel Hill Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
MacroGenics National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment-Emerging Adverse Events Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit. up to 77 days
Secondary AUC Inf: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity of MGD014 AUCinf, area under the concentration-time curve from the time of dose extrapolated to time infinity and reflects total drug exposure Study Day 0 to 42
Secondary Cmax: Maximum Plasma Concentration Cmax is the maximum (or peak) serum concentration of a drug in the body after the drug has been administered Study Day 0
Secondary Tmax: Time to Maximum Concentration Tmax is the time it takes a drug to reach the maximum concentration Study Day 0
Secondary Ctrough: Trough Level Concentration a trough level or trough concentration (Ctrough) is the concentration reached by a drug immediately before the next dose is administered, Study Day 14
Secondary Clearance Total body clearance of the drug from plasma of MGD014 Study Day 0 to 42
Secondary Vz: Terminal Phase Volume of Distribution of MGD014 The ratio of the total quantity of drug in the body to drug plasma concentration during the elimination Study Day 1, 2, 7, 14, 21, 28, and 42 (single infusion) and Study Day 1, 3, 14, 28, 42, and 77 (multiple infusions)
Secondary Terminal Half Life of MGD014 The half-life is the amount of time required for 50% of the drug to be removed from the body Study Day 0 to Study Day 42
Secondary Number of Participants That Developed Antidrug Antibodies to MGD014 Number of participants with antidrug antibodies to MGD014 Study Day 1, 14, 28 and 42 (single infusion) and Study Day 1, 14, 28 and 77 (multiple infusions)
Secondary Number of Participants With Increased Cytokine Levels Number of participants with increased cytokine levels from baseline after MGD014 administration. This safety measure compares serum cytokine levels obtained prior to dosing with levels obtained after dosing. Increased cytokines can be a measure of T-cell activation in response to MGD014 binding. Cytokines analyzed included interferon-gamma, tumor necrosis factor-alpha, interleukin (IL)2, IL-5, IL-6, and IL-10. Study Day 1, 2 and 7 (single infusion) and Study Day 1, 3, 14 and 28 (multiple infusions)
See also
  Status Clinical Trial Phase
Recruiting NCT03940521 - Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
Completed NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women Phase 2/Phase 3
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Active, not recruiting NCT04022967 - ANRS 12372 MODERATO Study Phase 3
Not yet recruiting NCT06282783 - Studying Topiramate for Re-Activating the HIV-1 Reservoir Phase 1/Phase 2
Not yet recruiting NCT06337032 - A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments Phase 4
Completed NCT04711265 - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Recruiting NCT03536234 - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients Phase 2
Completed NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease Phase 4
Withdrawn NCT05769569 - Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission Phase 1
Enrolling by invitation NCT05584397 - Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
Not yet recruiting NCT04894357 - Impact of V106I on Resistance to Doravirine
Completed NCT04963712 - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder Early Phase 1
Completed NCT04388904 - Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) Phase 4
Not yet recruiting NCT04513496 - Telemedicine in HIV Care in Buenos Aires
Completed NCT04568239 - Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Not yet recruiting NCT04311957 - Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults Phase 4
Not yet recruiting NCT04311944 - Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD N/A
Completed NCT03998176 - Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE Phase 4
Completed NCT04416906 - A Test and Treat Strategy in New HIV Diagnosis. Phase 3